Astria Therapeutics’ (ATXS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also issued reports on ATXS. Oppenheimer increased their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th. Wedbush reissued an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Down 7.1 %

Astria Therapeutics stock opened at $9.37 on Thursday. The firm has a 50-day moving average price of $11.40 and a two-hundred day moving average price of $10.62. The firm has a market capitalization of $528.66 million, a price-to-earnings ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Barclays PLC grew its stake in Astria Therapeutics by 70.5% in the 3rd quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after buying an additional 38,321 shares during the last quarter. Wellington Management Group LLP increased its position in Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after buying an additional 11,763 shares during the period. RA Capital Management L.P. lifted its holdings in shares of Astria Therapeutics by 1.2% during the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after buying an additional 61,457 shares during the last quarter. Redmile Group LLC bought a new position in Astria Therapeutics during the third quarter worth $3,423,000. Finally, Patient Square Capital LP bought a new position in Astria Therapeutics during the third quarter worth $434,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.